Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2008Cited by 253
Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Roberto Passera et al.|Journal of Clinical Oncology|2010Cited by 167
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Eva Hoster, Christine Hanoun et al.|The Lancet|2024Cited by 135
Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi SurveyCorrado Tarella, Alessandro Rambaldi, Manuela Zanni et al.|Journal of Clinical Oncology|2008Cited by 72
Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor RegistryRoberto Passera, Benedetto Bruno, Simona Pollichieni et al.|Biology of Blood and Marrow Transplantation|2013Cited by 21